Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration.
This retrospective chart review describes the efficacy and safety of long-term administration of intravenous alpha1-antitrypsin (AAT) in 14 patients with hereditary AAT deficiency and COPD. During the 12- to 48-month observation period, 12 to 14 patients had stabilization of functional status; 4 patients had reductions in hospitalizations. Thirteen of 14 patients had no decline in pulmonary function. Three patients had self-limited adverse reactions to the AAT with one patient requiring a brief hospitalization.
Barker
A F
AF
Department of Pulmonary and Critical Care Medicine, Oregon Health Sciences University, Portland.
Siemsen
F
F
Pasley
D
D
D'Silva
R
R
Buist
A S
AS
D000328:Adult; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007262:Infusions, Intravenous; D008173:Lung Diseases, Obstructive / Q000150:complications* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D012189:Retrospective Studies; D014797:Vital Capacity; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage* / Q000009:adverse effects; D019896:alpha 1-Antitrypsin Deficiency
D000515:alpha 1-Antitrypsin